Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: a preliminary study.
Sign Up to like & getrecommendations! Published in 2021 at "Bone"
DOI: 10.1016/j.bone.2021.116065
Abstract: BACKGROUND Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit… read more here.
Keywords: gip glp; gip; bone resorption;
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2020 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2020.154415
Abstract: BACKGROUND AND AIMS The reduced action of incretin hormones in type 2 diabetes (T2D) is mainly attributed to GIP insensitivity, but efficacy estimates of GIP and GLP-1 differ among studies, and the negligible effects of… read more here.
Keywords: t2d; type diabetes; gip; gip glp ... See more keywords
80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-80-lb
Abstract: Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist in development for type 2 diabetes (T2D). Efficacy and safety of TZP vs. placebo (PBO) was assessed in people with T2D as an add-on to titrated… read more here.
Keywords: company; lilly company; eli lilly; gip glp ... See more keywords
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1004044
Abstract: Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The development of novel dual- or triple-receptor agonists that bind to the receptors not only for… read more here.
Keywords: gip glp; type diabetes; treatment; receptor ... See more keywords
Associations between Postprandial Gut Hormones and Markers of Bone Remodeling
Sign Up to like & getrecommendations! Published in 2021 at "Nutrients"
DOI: 10.3390/nu13093197
Abstract: Gut-derived hormones have been suggested to play a role in bone homeostasis following food intake, although the associations are highly complex and not fully understood. In a randomized, two-day cross-over study on 14 healthy individuals,… read more here.
Keywords: gut; gut hormones; pyy; bone remodeling ... See more keywords
Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "Endokrynologia Polska"
DOI: 10.5603/ep.a2022.0029
Abstract: The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the… read more here.
Keywords: glp; dual gip; gip; gip glp ... See more keywords